Story perspectives

FDA Panel Raises Alarm on Antidepressant Safety in Pregnancy

8/29/2025

41 9

Summary

Story summary

A July 2025 FDA panel expressed concerns over the safety of antidepressants during pregnancy due to insufficient research.
Many women discontinue necessary treatments, jeopardizing maternal and fetal health.
Proposed budget cuts may hinder ongoing research efforts.
A systematic review indicated prenatal depression raises the risk of hypertensive disorders, with specific antidepressants showing different risk levels.
Further studies are essential to clarify these associations and guide treatment choices.

1 of 1

Story summary

A July 2025 FDA panel expressed concerns over the safety of antidepressants during pregnancy due to insufficient research.
Many women discontinue necessary treatments, jeopardizing maternal and fetal health.
Proposed budget cuts may hinder ongoing research efforts.
A systematic review indicated prenatal depression raises the risk of hypertensive disorders, with specific antidepressants showing different risk levels.
Further studies are essential to clarify these associations and guide treatment choices.